Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Deep Dive Review of Modelling Long Acting PrEP Meeting Summary

17 May 2023

In March 2023, the Bill and Melinda Gates Foundation convened modellers looking into the impact, costs, and/or cost effectiveness of cabotegravir (CAB) for PrEP in low and middle income countries. This meeting summary provides an overview of 11 models as well as key insights emerging from the models and knowledge gaps.

Topic(s): Research

Product(s): Cabotegravir, Injectable Prep

Format(s): Report

Source(s): Global Impact Advisors

Type: Document

Download

Featured Resources

Document

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…
Document

CAB PrEP Introduction Supply Chain Considerations – Kenya 2023

This document summarizes considerations for the integration of CAB PrEP within Kenya’s supply chain system based on interview with key national and subnational stakeholders.
Presentation

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention programs. In the…
Spreadsheet

Access Workbook for Cabotegravir for PrEP and Dapivirine Vaginal Ring

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP and the dapivirine vaginal ring (DVR) for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit product pricing, and information…
Presentation

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.
External Link

HPTN 083-02: Factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

This article from Journal of the International AIDS Society to explores the experiences of participants in the HPTN-083 trial, which evaluated safety and efficacy of cabotegravir for PrEP, including barriers to adherence and other factors that may have impacted study implementation or outcomes.
Document

MOSAIC (Maximizing Options to Advance Informed Choice for HIV Prevention)

Short introduction to MOSAIC, a project working across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide…
Document

Daily Oral PrEP, Event-Driven PrEP, PrEP Ring, and CAB PrEP Template Guidelines (Spanish)

The intent of this document is to provide adaptable guidelines to support the development and adoption of national guidelines that align with World Health Organization (WHO) pre-exposure prophylaxis (PrEP) recommendations and guidance, including those for tenofovir disoproxil fumarate (TDF)-based daily and event-driven oral PrEP, the monthly dapivirine vaginal ring (“PrEP ring” or “the ring”), and…
Document

AfroCAB’s Frequently Asked Questions on Cabotegravir for PrEP

This document, produced by AfroCAB, answers frequently asked questions that users may have about cabotegravir (CAB) for PrEP.
Document

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, March 2024

This document summarises key takeaways from a March 2024 BioPIC Think Tank to ensure modellers and implementation science researchers remain aligned on the latest cabotegravir for PrEP data and evidence.